NasdaqGM:ATAIPharmaceuticals
AtaiBeckley Advances BPL-003 Program As Beckley Psytech Deal Closes
AtaiBeckley (NasdaqGM: ATAI) published peer reviewed Phase 2a clinical trial results for BPL-003 in treatment resistant depression, reporting rapid and durable antidepressant effects with a favorable safety profile.
The company confirmed its Phase 3 trial timeline for BPL-003, targeting a Q2 2026 start following a completed FDA End of Phase 2 meeting.
AtaiBeckley completed the acquisition of Beckley Psytech Limited and re domiciled its corporate headquarters to Delaware, reshaping its...